Not the Sand Hill Way
This article was originally published in Start Up
G. Steven Burrill, for many years a consultant to the biotechnology industry through Ernst & Young and since 1993 a private merchant banker through his own San-Francisco based Burrill & Co. LLC, is now stepping into the role of venture capitalist. His first fund, geared to investment in agricultural biotechnology, has already collected $75 million. Burrill says he is more interested in getting strategic, rather than financial returns from the investments he'll make, and so are the corporations contributing to his new funds.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.